Want to see SRZN full AI Analyst Report?
Top Page
Surrozen
(NASDAQ:SRZN)
Select Model
Select Model
Rating:52Neutral
Price Target:
$25.00
▲(7.02% Upside)
Action:Reiterated
Date:10/13/26
The score is held back primarily by weak financial performance—very large losses, ongoing cash burn, and negative equity—despite a TTM revenue rebound. Technicals are broadly neutral, while valuation provides limited support due to negative earnings and no dividend. Offsetting these risks, the FDA IND clearance and associated expected financing proceeds are a meaningful positive corporate catalyst.
Positive Factors
Revenue Rebound
The revenue rebound indicates renewed activity in the company’s funding or collaboration-related business after a weak 2025. Although Surrozen remains pre-commercial, stronger reported revenue can provide incremental support for research execution and improve the platform’s financial trajectory if sustained.
Negative Factors
Severe Unprofitability
The scale of the net loss relative to $11.5M of TTM revenue shows that operating expenses remain far above the company’s current revenue base. Without substantial clinical or commercial scale, this cost structure can continue to pressure capital needs and limit financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The revenue rebound indicates renewed activity in the company’s funding or collaboration-related business after a weak 2025. Although Surrozen remains pre-commercial, stronger reported revenue can provide incremental support for research execution and improve the platform’s financial trajectory if sustained.
Read all positive factors
Surrozen (SRZN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$291.02M
Dividend YieldN/A
Average Volume (3M)766.61K
Price to Earnings (P/E)―
Beta (1Y)-0.11
Revenue Growth-8.79%
EPS Growth-195.46%
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-41.13
Shares Outstanding11,753,558
10 Day Avg. Volume659,012
30 Day Avg. Volume766,611
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap1.73
Enterprise Value/Revenue43.86
Enterprise Value/Gross Profit44.11
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$47.50Price Target Upside103.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-6.81
Revenue Forecast (FY)$10.75M
Surrozen Business Overview & Revenue Model
Company Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including dis...
How the Company Makes Money
Surrozen is not consistently revenue-generating from product sales because it is a clinical-stage biotech and, to the extent publicly available information indicates, does not have approved commercial therapeutics. The company’s funding and any re...
Surrozen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.51M | 3.48M | 10.65M | 0.00 | 12.50M | 0.00 |
| Gross Profit | 11.45M | 2.94M | 10.65M | -27.23M | 9.23M | -3.30M |
| EBITDA | -331.96M | -241.49M | -62.12M | -41.13M | -34.05M | -52.58M |
| Net Income | -332.13M | -242.03M | -63.56M | -43.04M | -36.00M | -52.51M |
Balance Sheet | ||||||
| Total Assets | 115.61M | 98.73M | 48.47M | 46.08M | 89.44M | 137.17M |
| Cash, Cash Equivalents and Short-Term Investments | 102.04M | 89.25M | 34.56M | 36.04M | 75.84M | 101.85M |
| Total Debt | 6.32M | 6.64M | 8.47M | 3.38M | 5.60M | 7.79M |
| Total Liabilities | 334.27M | 286.49M | 69.85M | 8.14M | 13.43M | 27.47M |
| Stockholders Equity | -218.66M | -187.76M | -21.38M | 37.94M | 76.00M | 109.70M |
Cash Flow | ||||||
| Free Cash Flow | -34.98M | -30.37M | -17.65M | -40.76M | -44.87M | -50.08M |
| Operating Cash Flow | -34.76M | -30.24M | -17.63M | -40.36M | -44.15M | -48.81M |
| Investing Cash Flow | -222.00K | -128.00K | -26.00K | 51.72M | 38.31M | -77.71M |
| Financing Cash Flow | 46.58M | 85.05M | 16.18M | 276.00K | -2.56M | 124.63M |
Surrozen Technical Analysis
Negative
23.36
Price Trends
23.61
Negative
23.43
Positive
24.71
Negative
Market Momentum
1.17
Positive
46.66
Neutral
32.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRZN, the sentiment is Negative. The current price of 23.36 is below the 20-day moving average (MA) of 25.18, below the 50-day MA of 23.61, and below the 200-day MA of 24.71, indicating a bearish trend. The MACD of 1.17 indicates Positive momentum. The RSI at 46.66 is Neutral, neither overbought nor oversold. The STOCH value of 32.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRZN.
Surrozen Risk Analysis
Surrozen disclosed 85 risk factors in its most recent earnings report. Surrozen reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Surrozen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $611.21M | -10.76 | -43.57% | ― | -66.63% | 57.89% | |
53 Neutral | $470.67M | -4.56 | -23.64% | ― | -76.20% | 52.86% | |
52 Neutral | $291.02M | -0.57 | 187.62% | ― | -8.79% | -195.46% | |
52 Neutral | $386.03M | -3.34 | 1147.63% | ― | -36.09% | 24.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $123.21M | -0.99 | -123.53% | ― | -100.00% | 52.43% | |
43 Neutral | $98.58M | -2.54 | -171.19% | ― | ― | 83.55% |
* Healthcare Sector Average
SRZN
Surrozen
23.51
9.87
72.36%
IRD
Opus Genetics
4.24
2.24
112.00%
OVID
Ovid Therapeutics
2.19
0.44
25.14%
STTK
Shattuck Labs
5.49
3.62
193.58%
SPRB
Spruce Biosciences
40.35
-136.56
-77.19%
BMEA
Biomea Fusion
1.26
-0.41
-24.55%
Surrozen Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Surrozen Wins FDA IND Clearance for SZN-8141 Program
Positive
Oct 2, 2026
Surrozen, Inc., a biotech developer of Wnt-modulating antibody therapies, reported on October 2, 2026, that the U.S. Food and Drug Administration cleared its Investigational New Drug application for SZN-8141, an intravitreal bifunctional Wnt agoni...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.